Navigation Links
Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
Date:10/26/2011

f having paralytic ileus or known hypersensitivity to any of its components or the active ingredient, buprenorphine, as well as those who require opioid analgesia for a short period of time, for the management of post-operative pain, including use after out-patient or day surgeries, the management of mild pain, and the management of intermittent pain (e.g., use on an as needed basis).  

The Full Prescribing Information for Butrans contains the following Boxed Warning:WARNING: IMPORTANCE OF PROPER PATIENT SELECTION, POTENTIAL FOR ABUSE, AND LIMITATIONS OF USEProper Patient SelectionButrans is a transdermal formulation of buprenorphine indicated for the management of moderate-to-severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Potential for Abuse Butrans contains buprenorphine which is a mu opioid partial agonist and a Schedule III controlled substance.  Butrans can be abused in a manner similar to other opioid agonists, legal or illicit.  Consider the abuse potential when prescribing or dispensing Butrans in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression).  Assess patients for their clinical risks for opioid abuse or addiction prior to being prescribed opioids.  Routinely monitor all patients receiving opioids for signs of misuse, abuse and addiction. Limitations of UseDo not exceed a dose of one 20 mcg/hour Butrans system due to the risk of QTc interval prolongation. Avoid exposing the Butrans application site and surrounding area to direct external heat sources. Temperature-dependent increases in buprenorphine release from the system may result in overdose and death.Summary of Clinical StudyThi
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
2. Purdue Pharma L.P. to Present Data From Clinical Program for Butrans™ (buprenorphine) Transdermal System CIII at PAINWeek® 2010
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
5. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
6. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
9. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
10. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
11. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015 Even the Score today announced the ... as scientific co-chair for the coalition. Dr. Larkin will ... an expert voice in the important conversation regarding the ... with Hypoactive Sexual Desire Disorder (HSDD), women,s most common ... honored to join Even the Score as its co-chair ...
(Date:7/27/2015)... 20, 2015 Research and Markets ( http://www.researchandmarkets.com/research/t63pbj/medical_device ... Device Regulation in Asia/Pacific Markets Seminar" conference to ... Medical Device market is well established, the next growth ... China , together with other countries in this ... of implementing, their own medical device regulations. This seminar ...
(Date:7/27/2015)... 27, 2015 Research and Markets ... of the "Wound Care -Traditonal, Advanced ... Analysis And Forecasts" report to their ... evaluation of the global Wound Care products ... product offerings, competitive shares, financial performance, technology ...
Breaking Medicine Technology:Dr. Lisa Larkin Joins the Even the Score Coalition as Scientific Co-Chair 2Dr. Lisa Larkin Joins the Even the Score Coalition as Scientific Co-Chair 3Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2
... Biopharmaceuticals, Inc. (NASDAQ: KERX ), a biopharmaceutical ... medically important pharmaceutical products for the treatment of cancer ... will be held on Monday, August 8, 2011 at ... quarter ended June 30, 2011 and a business outlook ...
... and SYDNEY, Aug. 4, 2011 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced revenues of $20.4 million for the second quarter ... increase from $9.8 million in revenues for the same ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results 2HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010 2HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010 3HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010 4HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010 5HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010 6
(Date:7/28/2015)... ... July 28, 2015 , ... The joint SCAN ... such as reducing high-risk medication use and improving compliance with diabetes treatment guidelines. ... behaviors and outcomes, this unique-in-the-industry Quality Network Program may be paving the way ...
(Date:7/28/2015)... ... July 28, 2015 , ... Headaches are the number one neurological ... close second. Clients suffering from headaches and back pain often find relief by seeking ... The Joint 's nine offices in the St. Louis area welcome new clients ...
(Date:7/28/2015)... ... 28, 2015 , ... North American Seminars will present seventeen ... 2015 . These seventeen courses are pre-approved for CME credit for Physical ... in the Older Adult , August 22, 2015 - August 23, 2015 ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... for Invisalign. Invisalign is a revolutionary orthodontic treatment that allows patients to straighten ... Mozafari’s expertise and 3D computer imaging technology. You wear each set of aligners ...
(Date:7/27/2015)... ... July 28, 2015 , ... Dr. Robert G. Schwartz ... practice has teamed up with Realief Neuropathy Centers in order to offer his patients ... the signs and symptoms of peripheral neuropathy. , Peripheral neuropathy is a disease caused ...
Breaking Medicine News(10 mins):Health News:SCAN/Express Scripts MA Pharmacy Quality Network Program to be Featured in Upcoming AIS Webinar 2Health News:SCAN/Express Scripts MA Pharmacy Quality Network Program to be Featured in Upcoming AIS Webinar 3Health News:The Joint St. Louis Offers “2 for Thursday” Special, Chiropractic Care Services, Affordable Back Pain Relief 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 3Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 5Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 6Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 7Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 8Health News:Cupertino Invisalign Dentist, Dr. Setareh Mozafari, is Now Offering Complimentary Consultations for Invisalign 2Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2
... a further death linked to the superbug Clostridium// difficile (C-diff). ... diarrhea and more serious intestinal conditions such as colitis. ... at the James Paget University Hospital (JPH), Gorleston, linked to ... people have had to undergo major bowel surgery. ...
... for space with stories on bird flu. After all, it ... that pets may be the only ones who need to ... insight, an arsenic-based additive that forms an ingredient in chicken ... this chicken. , ,Roxarsone, the wide spread arsenic-based ...
... for bipolar disorder, increases the amount// of gray matter ... ,The research is featured in the ... currently available online. ,Carrie Bearden, a ... and Paul Thompson, associate professor of neurology at the ...
... – Type 1 diabetic patients could be bailed out with ... ,Stem cell therapy proved helpful for patients suffering Type-1 ... for months and in one particular case a patient went ... participated in the testing, 13 completely stayed-off insulin injections. ...
... sufferer among Indian cities with flash rains, floods and fall ... an international report on climate change. ,According to the ... (IPCC), the rise in sea level and flooding of villages ... ,"Since Mumbai has reclaimed ocean land substantially, they are ...
... seeking judicial intervention for enactment of a law on the ... to instead approach the government. ,A division bench ... advocate Namita Roy to approach the ministries of social welfare ... valid laws, rules and regulation on the sensitive issue. ...
Cached Medicine News:Health News:Hospital Infection Deaths Continue in UK 2Health News:Lithium Increases Gray Matter in Bipolar Brains 2Health News:Kolkata, Mumbai to Face Maximum Brunt of Climate Change 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: